The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Dementias (AFTD) has awarded $300,000 to three academic scientists as part of the Frontotemporal Dementia Drug Discovery Program.

The awardees include Philip Van Damme of Leuven University (Belgium), Einar M Sigurdsson of New York University School of Medicine and W Haung Yu of The Taub Institute of Columbia University Medical Center.

The programme aims at accelerating the development of novel therapies for frontotemporal dementia (FTD).

The winners were chosen by an independent panel of 13 experts from the ADDF’s Scientific Review Board and AFTD’s Medical Advisory Council which evaluated 16 applications submitted from across the world.

FTD is the second most common cause of dementia under the age of 60 years having its onset between the ages of 40 and 65 years.